Novartis Splits Chair and CEO Positions, Names Joe Jimenez CEO
In a move that was somewhat abrupt, but hardly surprising, Novartis AG in late January announced that Joe Jimenez, who currently runs Novartis Pharma AG, would become the company's CEO, effective February 1. Long-time chairman and CEO David Vasella will remain as chairman. The announcement brings some closure to a process that began officially more than a year ago, as Novartis worked to get its succession planning right
You may also be interested in...
Medtech Insight sat down with Think Surgical’s CFO Paul Weiner at the recent AAOS conference to discuss the roll-out of the next-generation TSolution One TKA robot and company plans.
The US agency issued a letter to providers in the wake of a study that found significantly higher complication rates in women implanted with Boston Scientific’s Watchman device.
The company, which has reported no R&D successes outside of its CGRP inhibitor platform, said verdiperstat did not differentiate from placebo on any endpoints in multiple system atrophy.